Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CBST
- CUSIP: 22967810
- Web: N/A
- 50 Day Moving Avg: $101.00
- 200 Day Moving Avg: $85.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 52.55
- P/E Growth: 0
Frequently Asked Questions for Cubist Pharmaceuticals (NASDAQ:CBST)
What is Cubist Pharmaceuticals' stock symbol?
Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."
How were Cubist Pharmaceuticals' earnings last quarter?
Cubist Pharmaceuticals Inc (NASDAQ:CBST) posted its earnings results on Tuesday, October, 21st. The company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.54. The company earned $309.20 million during the quarter, compared to the consensus estimate of $305.50 million. The company's revenue for the quarter was up 16.2% on a year-over-year basis. During the same period last year, the firm posted $0.41 EPS. View Cubist Pharmaceuticals' Earnings History.
Who are some of Cubist Pharmaceuticals' key competitors?
Some companies that are related to Cubist Pharmaceuticals include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), Anavex Life Sciences Corp. (AVXL), Mirati Therapeutics (MRTX), XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Trillium Therapeutics (TRIL), Can Fite Biopharma Ltd (CANF), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY) and Dendreon (DNDN).
How do I buy Cubist Pharmaceuticals stock?
Shares of Cubist Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cubist Pharmaceuticals' stock price today?
MarketBeat Community Rating for Cubist Pharmaceuticals (NASDAQ CBST)MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cubist Pharmaceuticals stock can currently be purchased for approximately $101.94.
Consensus Ratings for Cubist Pharmaceuticals (NASDAQ:CBST) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cubist Pharmaceuticals (NASDAQ:CBST)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cubist Pharmaceuticals (NASDAQ:CBST)Earnings History by Quarter for Cubist Pharmaceuticals (NASDAQ CBST)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/21/2014||Q314||$0.04||$0.58||$305.50 million||$309.20 million||View||Listen|
|7/22/2014||Q214||$0.37||$0.23||$299.60 million||$294.40 million||View||N/A|
|4/22/2014||Q114||$0.34||$0.10||$285.24 million||$261.20 million||View||N/A|
|1/23/2014||Q413||$0.33||$0.29||$285.47 million||$299.70 million||View||N/A|
|7/18/2013||Q2 2013||$0.55||$0.42||$254.93 million||$258.80 million||View||N/A|
|4/18/2013||Q1 2013||$0.50||$0.34||$243.55 million||$229.90 million||View||N/A|
|1/23/2013||Q4 2012||$0.48||$0.51||$246.42 million||$245.90 million||View||N/A|
Earnings Estimates for Cubist Pharmaceuticals (NASDAQ:CBST)
Current Year EPS Consensus Estimate: $1.14 EPS
Next Year EPS Consensus Estimate: $1.94 EPS
Dividend History for Cubist Pharmaceuticals (NASDAQ:CBST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cubist Pharmaceuticals (NASDAQ:CBST)Insider Trades by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/1/2014||Steven C Gilman||EVP||Sell||48,125||$65.39||$3,146,893.75|| |
|8/19/2014||Gregory Stea||SVP||Sell||38,326||$65.88||$2,524,916.88|| |
|8/18/2014||Nancy J Hutson||Director||Sell||9,000||$65.00||$585,000.00|| |
|8/18/2014||Robert J Perez||COO||Sell||1,003||$63.68||$63,871.04|| |
|7/28/2014||Steven C Gilman||EVP||Sell||40,625||$61.57||$2,501,281.25|| |
|5/15/2014||Michael Bonney||CEO||Sell||3,036||$67.50||$204,930.00|| |
|5/15/2014||Robert Perez||COO||Sell||1,518||$67.50||$102,465.00|| |
|5/15/2014||Steven Gilman||EVP||Sell||16,340||$67.82||$1,108,178.80|| |
|5/14/2014||Michael Bonney||CEO||Sell||3,840||$69.00||$264,960.00|| |
|5/14/2014||Robert Perez||COO||Sell||2,400||$69.00||$165,600.00|| |
|5/14/2014||Steven Gilman||EVP||Sell||1,680||$69.00||$115,920.00|| |
|3/6/2014||Gregory Stea||SVP||Sell||19,889||$79.74||$1,585,948.86|| |
|2/27/2014||Mark Corrigan||Director||Sell||5,000||$80.00||$400,000.00|| |
|2/27/2014||Michael Bonney||CEO||Sell||100,000||$81.25||$8,125,000.00|| |
|2/27/2014||Robert Perez||COO||Sell||30,000||$80.18||$2,405,400.00|| |
|2/20/2014||Michael Bonney||CEO||Sell||3,112||$75.60||$235,267.20|| |
|2/3/2014||Kenneth Bate||Director||Sell||6,250||$72.15||$450,937.50|| |
|1/15/2014||Gregory Stea||SVP||Sell||5,312||$74.90||$397,868.80|| |
|1/15/2014||Robert Perez||COO||Sell||10,000||$74.95||$749,500.00|| |
|1/13/2014||Robert Perez||COO||Sell||10,000||$72.95||$729,500.00|| |
|1/9/2014||Kenneth Bate||Director||Sell||10,000||$70.00||$700,000.00|| |
|1/2/2014||Steven Gilman||EVP||Sell||25,000||$67.82||$1,695,500.00|| |
|12/2/2013||Kenneth Bate||Director||Sell||12,500||$67.63||$845,375.00|| |
|9/9/2013||Martin Rosenberg||Director||Sell||15,472||$65.00||$1,005,680.00|| |
|8/16/2013||Robert Perez||COO||Sell||1,024||$60.55||$62,003.20|| |
|7/31/2013||Gregory Stea||SVP||Sell||33,750||$61.29||$2,068,537.50|| |
|7/26/2013||Nancy J Hutson||Director||Sell||5,000||$53.87||$269,350.00|| |
|7/19/2013||Gregory Stea||SVP||Sell||4,375||$55.00||$240,625.00|| |
|6/3/2013||Kenneth Bate||Director||Sell||2,500||$54.95||$137,375.00|| |
|6/3/2013||Steven C Gilman||EVP||Sell||15,125||$54.49||$824,161.25|| |
|5/24/2013||Mark Corrigan||Director||Sell||14,000||$54.60||$764,400.00|| |
|5/22/2013||J Matthew Singleton||Director||Sell||27,500||$55.48||$1,525,700.00|| |
|5/20/2013||Charles Anthony Laranjeira||SVP||Sell||14,000||$51.43||$720,020.00|| |
|5/20/2013||Michael W Bonney||CEO||Sell||60,000||$50.00||$3,000,000.00|| |
|5/20/2013||Robert J Perez||COO||Sell||15,000||$49.98||$749,700.00|| |
|5/16/2013||Michael W Bonney||CEO||Sell||2,400||$47.88||$114,912.00|| |
|5/16/2013||Robert J Perez||COO||Sell||1,500||$47.88||$71,820.00|| |
|5/16/2013||Steven C Gilman||EVP||Sell||1,201||$48.88||$58,704.88|| |
|5/15/2013||Kenneth Bate||Director||Sell||2,500||$48.41||$121,025.00|| |
|5/15/2013||Michael W Bonney||CEO||Sell||2,979||$48.41||$144,213.39|| |
|5/15/2013||Robert J Perez||COO||Sell||1,490||$48.41||$72,130.90|| |
|5/15/2013||Steven C Gilman||EVP||Sell||1,017||$48.41||$49,232.97|| |
|5/14/2013||Michael W Bonney||CEO||Sell||3,753||$49.18||$184,572.54|| |
|5/14/2013||Robert J Perez||COO||Sell||2,346||$49.18||$115,376.28|| |
|5/14/2013||Steven C Gilman||EVP||Sell||1,135||$49.18||$55,819.30|| |
Headline Trends for Cubist Pharmaceuticals (NASDAQ:CBST)
Latest Headlines for Cubist Pharmaceuticals (NASDAQ:CBST)
Cubist Pharmaceuticals (CBST) Chart for Wednesday, July, 26, 2017